General Information
Alnylam Mild-Mod HTN 002
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension
| Protocol | ALN-AGT01-002 |
|---|---|
| Identifier | |
| UID | 695bb5c8-4a6a-4c41-b437-26575e221ea9 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Hypertension / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2021-10-25 12:30 |
| Last Updated | 2023-08-04 17:51 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2022-03-21 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-02-02 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2023-07-19 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Alnylam Pharmaceuticals, Inc. |
|---|---|
| Division | Alnylam Pharmaceuticals, Inc. |
| Team | Alnylam Pharmaceuticals, Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
